We recently published our article 5 Fast-Growing AI Healthcare Companies to Watch Right Now. To read the full article, head on to 10 Fast-Growing AI Healthcare Companies to Watch Right Now. In this piece, we take a closer look at Guardant Health Inc. (NASDAQ:GH) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.

Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.

Why Medicine Could Be AI’s Next Major Market

Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.

Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.

These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.

A Low Share Price Does Not Always Mean Cheap

A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.

The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.

Finding the Best AI Medicine Stocks

This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.

The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.

CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.

Our Methodology

For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.

5 Best Cheap AI Medicine Stocks to Buy Now

3. Guardant Health Inc. (NASDAQ:GH)

Guardant Health, Inc. (NASDAQ: GH) takes third place as one of the strongest publicly traded companies in liquid biopsy and precision oncology.

The company develops blood-based tests that analyze genetic material released by cancer cells. Its products can help identify appropriate treatments, monitor patients for cancer recurrence and screen certain individuals for early signs of disease.

Artificial intelligence and machine learning are important because the company must distinguish meaningful cancer-related signals from enormous amounts of biological information. As its testing volumes increase, the resulting data can potentially improve product performance and strengthen its competitive position.

Second-quarter 2026 revenue surged 44% to $335 million. Oncology revenue increased 38% to approximately $219.1 million, while screening revenue grew by more than 250% to $52.9 million.

The Shield colorectal cancer screening test was a major contributor. Quarterly Shield volume reached approximately 66,000 tests, compared with around 16,000 during the prior-year period.

Management increased its full-year revenue guidance by $40 million to approximately $1.35 billion, representing expected annual growth of between 36% and 38%.

These results suggest that Guardant Health, Inc. (NASDAQ: GH) is moving from technological promise toward large-scale commercial adoption. Its products now address multiple stages of cancer care, from screening to treatment selection and recurrence monitoring.

The risks remain considerable. The company recorded a second-quarter net loss of approximately $120.1 million, compared with a $99.9 million loss one year earlier. Commercial expansion and marketing for Shield continue to require substantial spending.

The company is also dealing with a patent dispute that could result in damages and continuing royalty obligations. While management plans to challenge the ruling, investors must include that legal uncertainty in their assessment.

Guardant Health, Inc. (NASDAQ: GH) still earns third place because few artificial intelligence healthcare companies combine comparable revenue growth with such a large medical opportunity. If Shield gains broader insurance coverage and oncology testing continues expanding, the company could become an increasingly important part of cancer diagnosis and monitoring.

YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.